Literature DB >> 9692080

Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival.

L J Melton1, T M Therneau, D R Larson.   

Abstract

In this population-based descriptive study covering the 65-year period, 1928-92, there was a 5-fold increase in hip fracture prevalence among Rochester, Minnesota residents between 1928-42 and 1973-82, from 135.8 to 675.8 per 100,000. This change was dictated almost entirely by an increase in the incidence of first hip fractures due to moderate trauma (n = 2058) that was observed among Rochester women through 1950, and among men through 1980, that affected all age groups. Declining incidence rates thereafter led to a 9% fall in hip fracture prevalence from 1973-82 to 1983-92 to a rate of 612.7 per 100,000. A 13.7-year increase in age at first hip fracture over the study period was accounted for by aging of the underlying population, and a comparable 13.9-year increase in the age at death following hip fracture appeared to result from improved survival in the population generally. Thus, trends in hip fracture prevalence were mainly determined by changes in incidence rather than relative changes in age at onset and death following hip fracture.

Entities:  

Mesh:

Year:  1998        PMID: 9692080     DOI: 10.1007/s001980050050

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  36 in total

1.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

2.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.

Authors:  Celine M Vachon; Robert A Kyle; Terry M Therneau; Barbara J Foreman; Dirk R Larson; Colin L Colby; Tara K Phelps; Angela Dispenzieri; Shaji K Kumar; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

3.  Mortality after osteoporotic fractures.

Authors:  O Johnell; J A Kanis; A Odén; I Sernbo; I Redlund-Johnell; C Petterson; C De Laet; B Jönsson
Journal:  Osteoporos Int       Date:  2003-10-30       Impact factor: 4.507

4.  Excess mortality after hospitalisation for vertebral fracture.

Authors:  John A Kanis; Anders Oden; Olof Johnell; Chris De Laet; Bengt Jonsson
Journal:  Osteoporos Int       Date:  2003-11-04       Impact factor: 4.507

5.  Quality of life, morbidity, and mortality after low trauma hip fracture in men.

Authors:  I Pande; D L Scott; T W O'Neill; C Pritchard; A D Woolf; M J Davis
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

Review 6.  Osteoporosis in men.

Authors:  Sundeep Khosla; Shreyasee Amin; Eric Orwoll
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

7.  Geographic variation in osteoporotic hip fracture incidence: the growing importance of asian influences in coming decades.

Authors:  D K Dhanwal; C Cooper; E M Dennison
Journal:  J Osteoporos       Date:  2010-08-02

8.  Functional decline after incident wrist fractures--Study of Osteoporotic Fractures: prospective cohort study.

Authors:  Beatrice J Edwards; Jing Song; Dorothy D Dunlop; Howard A Fink; Jane A Cauley
Journal:  BMJ       Date:  2010-07-08

9.  Cost-effective osteoporosis treatment thresholds: the United States perspective.

Authors:  A N A Tosteson; L J Melton; B Dawson-Hughes; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

10.  Updated fracture incidence rates for the US version of FRAX.

Authors:  B Ettinger; D M Black; B Dawson-Hughes; A R Pressman; L J Melton
Journal:  Osteoporos Int       Date:  2009-08-25       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.